Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Lenvatinib in Anaplastic Thyroid Cancer
NCT06374602Phase 2Recruiting
- Sponsor
- Saint Petersburg State University
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in anaplastic thyroid cancer (ATC), sponsored by Saint Petersburg State University. Started Mar 2024; status: recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT06374602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06374602.